Indeed, biomarkers for neurodegeneration, that is, MRI measurements for brain atrophy, fluorodeoxyglucose‐positron emission tomography (FDG‐PET) hypometabolism, and CSF tau measures, are also included in the 2018 framework, but are considered neither necessary nor sufficient for an AD diagnosis.29 This evidence concerns the gene MAPT and Alzheimer disease.